Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1

Lookup NU author(s): Dr Long Xie

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2019, Springer-Verlag GmbH Austria, part of Springer Nature. The long-term administration of acyclovir (ACV) for therapy against herpes simplex virus type 1 (HSV-1) infections can result in the emergence of ACV-resistant HSV strains. It is therefore urgent to develop new anti-herpetic compounds with mechanisms that differ from that of ACV. Cyanovirin-N (CV-N) is an antiviral agent that has an inhibitory effect on HSV-1 infections, and PEGylation of CV-N is potentially useful for pharmaceutical applications. Here, a (Gly 4 Ser) 3 linker molecule was attached to the N-terminus of CV-N, and the resulting compound, linker-CV-N (LCV-N), was produced on a pilot scale with purity up to 95%. Then, PEG 10k -LCV-N was synthesized by modifying at the α-amine group of the N-terminus of LCV-N with 10-kDa polyethylene glycol propionaldehyde (mPEG-ALD). CV-N, LCV-N and PEG 10k -LCV-N were all found to have potent inhibitory activity against ACV-resistant HSV strains with IC 50 values in the nM range. LCV-N was the most potent of these three compounds against both normal and ACV-resistant HSV strains. Although PEG 10k -LCV-N showed less antiviral activity than CV-N and LCV-N, it still exhibited significant and universal virucidal activity against drug-resistant viruses. The toxicity and immunogenicity of PEG 10k -LCV-N were dramatically lower than those of CV-N and LCV-N. In conclusion, we suggest that LCV-N and PEG 10k -LCV-N are promising and safe microbicides for the control and/or treatment of ACV-resistant HSV infection.

Publication metadata

Author(s): Lei Y, Chen W, Liang H, Wang Z, Chen J, Hong H, Xie L, Nie H, Xiong S

Publication type: Article

Publication status: Published

Journal: Archives of Virology

Year: 2019

Volume: 164

Issue: 5

Pages: 1259-1269

Print publication date: 01/05/2019

Online publication date: 23/03/2019

Acceptance date: 13/11/2018

ISSN (print): 0304-8608

ISSN (electronic): 1432-8798

Publisher: Springer Vienna

URL: https://doi.org/10.1007/s00705-018-04118-4

DOI: 10.1007/s00705-018-04118-4

Altmetrics

Altmetrics provided by Altmetric

Share